A comprehensive review of the “millions of lives saved” hoax

This study published in the Journal of Applied Biology and Pharmaceutical Technology concisely summarizes everything we’ve been saying about the half-baked and dubious assumptions underpinning the simulation models claiming millions of lives were saved by the modRNA transfections used as COVID vaxx especially the 95% VE claim that never held up outside the clinical trials. The overly optimistic assumptions in these simulation models used to claim the vaxx “saved millions of lives” did not include early supply bottle necks, population heterogeneity, variable social behavior between vaxxed and unvaxxed, healthy vaccinee bias, waning immunity, and the emergence of immune escape variants (omnicron). Instead they (falsely) assumed that vaxx rollout and uptake would proceed without logistical barriers or supply issues, that public compliance would be uniform throughout countries, the testing rates between vaxx and unvaxxed were equal and that population level immunity was static. They relied on public health dashboards and observational studies to make these assumptions instead of the actual clinical trials. The actual COMIRNATY Phase III clinical trial showed no statistically significant difference in all cause mortality between the Vaxx arm and the placebo arm with the vaxx arm actually having slightly more deaths (21) than the placebo arm (17). There were also too few deaths attributed to COVID-19 (7) across the 44,000 participants to reach a statistical significant reduction of those deaths either. The 95% VE figure came from the 162 cases vs. 8 cases split between the vaxx arm and placebo arm; however, the placebo blinded phase only lasted 4 months and 13 days before all participants were unblinded, which is not nearly long enough to concur durable risk reduction against symptomatic COVID-19, especially considering most vaccine trials are conduct for years not a matter of a few months.